Skip to main content
logo
Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.580
-0.140 (-3.76%)
At close: Jul 31, 2026, 4:00 PM EDT
3.590
+0.010 (0.28%)
After-hours: Jul 31, 2026, 7:59 PM EDT

Fulcrum Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--802.816.3419.16
Revenue Growth
--2752.05%-55.77%-66.91%117.19%
Gross Profit
--802.816.3419.16
Selling, General & Admin
30.428.6736.4541.6741.6930.52
Research & Development
56.2456.163.3971.876.7869.7
Other Operating Expenses
5.09-2.06-0.43-
Total Operating Expenses
91.7384.77101.9113.47118.9100.22
Operating Income
-96.05-84.77-21.9-110.66-112.56-81.05
Total Non-Operating Income (Expense)
11.059.8912.1713.332.690.21
Pretax Income
-85-74.88-9.73-97.34-109.87-80.85
Net Income
-19.6-74.88-9.73-97.34-109.87-80.85
Net Income to Common
-19.6-74.88-9.73-97.34-109.87-80.85
Net Income Growth
------
Shares Outstanding (Basic)
706362614535
Shares Outstanding (Diluted)
706362614535
Shares Change
16.35%2.21%1.10%36.27%27.23%39.47%
EPS (Basic)
-1.21-1.18-0.16-1.59-2.44-2.29
EPS (Diluted)
-1.21-1.18-0.16-1.59-2.44-2.29
EPS Growth
------
Free Cash Flow
-66.14-60.38-2.5-91.47-99.01-80.19
Free Cash Flow Growth
------
Free Cash Flow Per Share
-0.94-0.95-0.04-1.49-2.20-2.27
Gross Margin
--100.00%100.00%100.00%100.00%
Operating Margin
---27.37%-3945.24%-1774.85%-422.97%
Profit Margin
---12.16%-3470.05%-1732.43%-421.89%
FCF Margin
---3.12%-3261.07%-1561.23%-418.47%
EBITDA
-94.8-83.38-20.3-108.49-110.15-78.54
EBITDA Margin
---25.38%-3867.81%-1736.79%-409.85%
EBIT
-96.05-84.77-21.9-110.66-112.56-81.05
EBIT Margin
---27.37%-3945.24%-1774.85%-422.97%
SEC Filings: 10-K · 10-Q